Reliance Industries' subsidiary, Strand Life Sciences, has achieved a significant milestone by securing an Indian patent for an innovative AI-driven blood test aimed at early-stage cancer detection.
The patent, granted on July 7, 2026, pertains to a platform that utilizes cell-free DNA analysis. This advanced technology integrates high-quality genome sequencing with machine learning techniques to extract critical features, including methylation and fragmentomic data, from a single blood sample. The goal is to enhance the accuracy, scalability, and accessibility of precision cancer screening, especially crucial in a country where over 1.5 million new cancer cases are reported annually.
According to CEO Ramesh Hariharan, this development exemplifies the transition of machine learning models from research settings to practical clinical applications, signifying a step forward in the use of advanced genomic techniques for real-world healthcare solutions.
This patent not only highlights the technological advancements in cancer diagnostics but also underscores the potential impact on public health in India, where early detection can significantly improve treatment outcomes.